Neurogenic bladder is a common condition associated with traumatic spinal cord injuries (SCIs), which results in inhibited detrusor function, bladder-sphincter dyssynergia, and scarring of the bladder walls and muscle. Care for neurogenic bladder is aimed at reducing abnormally high pressures, which left untreated lead to hypertrophy and tissue fibrosis of the bladder wall, as well as upper urinary tract complications. Current treatments target the neurotransmitter release of acetylcholine, utilizing anticholinergic drugs to counter the overactive bladder. However, these drugs can have negative/deleterious side effects, and have broad symptoms influencing unintended targets around the body. Targeted chemodenervation that uses Botulinum toxin (Botox) to interfere with nerve conduction is often reserved as a second line of defense to treat neurogenic bladder. Unfortunately, this late provision concedes irreversible damage to the detrusor muscle. We hypothesize that administering early chemodenervation can prevent the development of neurogenic bladder, improve bladder compliance post SCI, and increase the overall quality of life of SCI affected patients. Using a rat model, the Khaing lab administers a controlled contusion injury to the T8/T9 vertebrae, simulating a spinal cord injury in humans. The recovery of the rats is tracked with behavioral observations, cystometry data collection, and histological stains. My team and I are working to determine the effective therapeutic time post SCI for Botox injections, and the optimal doses for treatment. Our results thus far support that acute chemodenervation with Botox reduces bladder overactivity, and bladder wall thickness.